Lunai Bioworks (LNAI) Assets Average (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Assets Average of $8.3 million for Q1 2026, down 92.79% year-over-year from $114.5 million in Q1 2025, and up 21.28% quarter-over-quarter from $6.8 million in Q4 2025.
Lunai Bioworks (LNAI) Assets Average (2011 - 2026) Analysis & Trends
Lunai Bioworks' Assets Average history runs 16 years deep, the most recent figure standing at $8.3 million for Q1 2026.
- In Q1 2026, Assets Average fell 92.79% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (down 92.79% YoY), while the FY2025 annual figure was $85.7 million, down 22.61% from the prior year.
- Assets Average for Q1 2026 stood at $8.3 million, up from $6.8 million in the prior quarter.
- The five-year high for Assets Average was $181.6 million in Q1 2022, with the low at $6.8 million in Q4 2025.
- The 5-year median for Assets Average is $81.7 million (2022), against an average of $87.7 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average surged 149.01% in 2024, then plunged 94.67% in 2025.
- Lunai Bioworks' Assets Average stood at $81.7 million in 2022, then decreased by 29.24% to $57.8 million in 2023, then soared by 101.74% to $116.6 million in 2024, then plunged by 94.16% to $6.8 million in 2025, then rose by 21.28% to $8.3 million in 2026.
- Business Quant data shows LNAI's Assets Average at $8.3 million in Q1 2026, $6.8 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 8.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.26 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Sep 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 62.98 Mn |
| Mar 31, 2025 | 114.53 Mn |
| Dec 31, 2024 | 116.59 Mn |
| Sep 30, 2024 | 142.48 Mn |
| Jun 30, 2024 | 170.61 Mn |
| Mar 31, 2024 | 118.05 Mn |
| Dec 31, 2023 | 57.79 Mn |
| Sep 30, 2023 | 57.93 Mn |
| Jun 30, 2023 | 68.52 Mn |
| Mar 31, 2023 | 79.50 Mn |
| Dec 31, 2022 | 81.67 Mn |
| Sep 30, 2022 | 83.85 Mn |
| Jun 30, 2022 | 132.37 Mn |
| Mar 31, 2022 | 181.62 Mn |
| Dec 31, 2021 | 183.60 Mn |
| Sep 30, 2021 | 186.83 Mn |
| Jun 30, 2021 | 181.65 Mn |